Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics
Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.
How this was made
The 30-second read
Why it matters
The disclosed preclinical mechanism provides a tangible proof‑of‑concept, potentially de‑risking the program and attracting partner interest.
Market read
First‑time disclosure of SIL204 preclinical data triggered a sharp price surge, indicating immediate market relevance for SLXN.
What to watch
Funding runway and upcoming Phase 2/3 enrollment timelines could constrain upside.
Background
Silexion Therapeutics (NASDAQ:SLXN) is a clinical‑stage biotech focused on RNA‑i therapies for KRAS‑driven cancers. The company has a market cap of ~ $1.4 M and shares have fallen 99% over the past year.
Ticker impact
Silexion Therapeutics disclosed positive preclinical data for its lead KRAS‑targeting candidate SIL204, driving a 61% after‑hours price jump.
likely continued upward pressure as the market prices in the translational milestone.
The data are the first public disclosure of SIL204’s mechanism, a material catalyst for a micro‑cap biotech.
Market effects
May boost sentiment toward RNA‑interference and KRAS‑targeted biotech peers.
Limited to U.S. biotech micro‑caps; no broader regional effect.
Low global impact beyond niche oncology investors.
Counterpoint
The preclinical data may not translate to clinical success; the rally could be premature.
Key entities
- ExecutiveDr. Mitchell Shirvan
Chief Scientific and Development Officer, highlighted the mechanistic milestone.
- ExecutiveIlan Hadar
Chairman and CEO, emphasized the data’s relevance to the subcutaneous delivery strategy.